Amenorrhea and Menopause in Patients with Breast Cancer after Chemotherapy

Jae Jun Shin; Young Min Choi; Jong Kwan Jun; Kyung-Hun Lee; Tae-Yong Kim; Wonshik Han; Seock-Ah Im

추천

검색

자료유형: 학술저널

저자정보: Jae Jun Shin (Department of Obstetrics and Gynecology Seoul National University College of Medicine Seoul Korea) Young Min Choi (Department of Obstetrics and Gynecology Seoul National University College of Medicine Korea) Jong Kwan Jun (Department of Obstetrics and Gynecology Seoul National University College of Medicine Seoul Korea) Kyung-Hun Lee (Department of Internal Medicine Seoul National University College of Medicine Seoul Korea) Tae-Yong Kim (Department of Internal Medicine Seoul National University College of Medicine Seoul Korea) Wonshik Han (Department of Surgery Seoul National University College of Medicine Cancer Research Institute Seoul) Seock-Ah Im (Internal Medicine Seoul National University College of Medicine Seoul; Cancer Research Institute Se)

저널정보: 한국유방암학회 Journal of Breast Cancer Journal of Breast Cancer Vol.22 No.4

발행연도: 2019.1

수록면: 624 - 634 (11page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: The probability of ovarian failure after cytotoxic chemotherapy in patients with breast cancer has not been well established in Korea. This study aimed to assess the rate of ovarian failure in a large cohort of Korean premenopausal patients with breast cancer 12 months after chemotherapy. Methods: This retrospective cohort study included premenopausal women (aged 20−44 years) with breast cancer who underwent chemotherapy after surgery. The rates of treatment-related amenorrhea (TRA) and chemotherapy-induced menopause (CIM) at 12 months after chemotherapy were analyzed. Results: A total of 237 patients met the inclusion criteria. The rate of TRA was 61.6% and that of CIM was 13.1% at 12 months after chemotherapy. The rates of TRA and CIM were 28.0% and 4.0%, respectively, in women aged 25−34 years, and they gradually increased up to 75.9% (TRA) and 15.8% (CIM), respectively, in women aged 40−44 years. The frequency of CIM was significantly lower than that of TRA in both age groups. In multivariate analyses, only tamoxifen use was significantly associated with a decreased risk of CIM (p < 0.001). Age of 40 years or higher and the regimens of doxorubicin plus cyclophosphamide followed by docetaxel or paclitaxel were associated with increased risk of TRA (p = 0.001 and p = 0.002, respectively). Conclusion: Marked discrepancy in the rates of CIM and TRA was observed in this study. Further, the age-specific frequency of CIM and TRA observed in this study is a reliable and practical estimate of the risks of CIM and TRA in the absence of gonadal protection.

#Age groups #Amenorrhea #Breast neoplasms #Drug therapy #Menopause

참고문헌 (30)

참고문헌 신청

박은화 / 2017 / Basic Facts of Breast Cancer in Korea in 2014: The 10-Year Overall Survival Progress / Journal of Breast Cancer 20(1):1~11

정규원 / 2017 / Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014 / Cancer Research and Treatment 49(2):292~305

American Cancer Society / Breast cancer facts & figures, 2015–2016

Fredholm H / 2009 / Breast cancer in young women : poor survival despite intensive treatment / PLoS One 4:e7695

Yu B / 2010 / Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy / Cancer 116:2099~2105

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

Jae Jun Shin

소속기관 Department of Obstetrics and Gynecology Seoul National University College of Medicine Seoul Korea.F